Snapshot from Jul 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Regeneron securities class action lawsuit
Regulatory securities class action

Regeneron securities class action lawsuit

Analysis based on 7 articles · First reported Jul 21, 2026 · Last updated Jul 30, 2026

Sentiment
-40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Regeneron's stock price dropped approximately 13.95% following disclosures of a protocol amendment and trial failure, erasing about $102 per share in value. The lawsuit may lead to financial penalties and increased scrutiny of Regeneron's clinical trial disclosures, potentially affecting investor confidence in the company's pipeline.

Biotechnology Pharmaceuticals
Event Summary

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of shareholders who purchased REGN securities between August 1, 2025 and May 15, 2026. The lawsuit, filed by Levi & Korsinsky LLP on behalf of SueWallSt, alleges that Regeneron made materially false and misleading statements regarding the Phase III Fianlimab-Libtayo Study. Specifically, the complaint claims that Regeneron minimized the clinical, statistical, and regulatory risks, including the impact of FDA Optimus-related protocol amendments on progression-free survival analysis. The lawsuit alleges that slowing event accrual was characterized as potentially favorable, while the study faced heightened risk of failing its primary endpoint. On April 29, 2026, Regeneron disclosed a protocol amendment expanding the PFS analysis population, and on May 15, 2026, announced that the trial did not reach statistical significance for the primary endpoint of improved PFS. REGN shares declined approximately 13.95% ($102.09 per share) from the Class Period high of $731.77 on April 28, 2026 to $629.68. The lead plaintiff deadline is September 14, 2026. Ryan Crowe, Regeneron's Senior Vice President of Investor Relations, is named as an individual defendant for allegedly making misleading statements to investors.

Key Actions
100 Regeneron Pharmaceuticals disclosed trial failure
90 Levi & Korsinsky notified investors of lawsuit Regeneron Pharmaceuticals
80 Regeneron Pharmaceuticals announced trial expansion
70 Ryan Crowe made allegedly misleading statements
Entities Involved
stock
Regeneron Pharmaceuticals
Regeneron is the defendant in a securities class action lawsuit alleging misleading statements about its Phase III Fianlimab-Libtayo Study. The stock declined 13.95% after the trial failed to meet its primary endpoint, and the company faces potential financial liability and reputational damage.
Importance 100.0 Sentiment -60.0
per
Ryan Crowe
Ryan Crowe, Regeneron's Senior Vice President of Investor Relations, is named as an individual defendant for allegedly making misleading statements about the Phase III trial. He faces personal liability under securities laws.
Importance 50.0 Sentiment -40.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm representing the plaintiff class in the securities class action against Regeneron. The firm stands to gain attorneys' fees if the case is successful.
Importance 40.0 Sentiment 10.0
per
Joseph E. Levi
Joseph E. Levi is the attorney from Levi & Korsinsky representing the plaintiffs. He is quoted in the press releases commenting on the case.
Importance 30.0 Sentiment 5.0
govactor
United States — United States Securities and Exchange Commission
The SEC is referenced in the context of disclosure adequacy issues. The lawsuit alleges that Regeneron's disclosures violated securities laws enforced by the SEC.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA's Optimus requirements are mentioned as part of the regulatory risks that Regeneron allegedly failed to disclose adequately.
Importance 15.0 Sentiment 0.0
govactor
United States — United States District Court for the Southern District of New York
The case was filed in this court, which will oversee the litigation.
Importance 10.0 Sentiment 0.0
Relationships
Regeneron Pharmaceuticals related ↔ United States — Food and Drug Administration
Levi & Korsinsky related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ United States — United States Securities and Exchange Commission
Levi & Korsinsky related ↔ United States — Food and Drug Administration
Joseph E. Levi related ↔ United States — United States Securities and Exchange Commission
Joseph E. Levi related ↔ United States — Food and Drug Administration
United States — United States Securities and Exchange Commission related ↔ United States — Food and Drug Administration
United States — United States Securities and Exchange Commission related ↔ United States — United States District Court for the Southern District of New York
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.